MEDIFAST INC

For the period ended Dec 31, 2023. Filed Feb 20, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 20, 2024

MED$13.37+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDIFAST, INC.

By:	/s/ DANIEL R. CHARD
	Daniel R. Chard
	Chief Executive Officer
	(Principal Executive Officer)
Dated:	February 20, 2024
	/s/ JAMES P. MALONEY
	James P. Maloney
	Chief Financial Officer
	(Principal Financial Officer)
Dated:	February 20, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

Jeffrey J. Brown
Name	Title	Date
/s/ JEFFREY J. BROWN	Lead Director	February 20, 2024
/s/ DANIEL R. CHARD	Chairman and Chief Executive Officer	February 20, 2024
Daniel R. Chard
/s/ ELIZABETH A. GEARY	Director	February 20, 2024
Elizabeth A. Geary
/s/ MICHAEL A. HOER	Director	February 20, 2024
Michael A. Hoer
/s/ JONATHAN B. MACKENZIE	Vice President Finance and Chief Accounting Officer	February 20, 2024
Jonathan B. MacKenzie
/s/ JAMES P. MALONEY	Chief Financial Officer	February 20, 2024
James P. Maloney
/s/ SCOTT SCHLACKMAN	Director	February 20, 2024
Scott Schlackman
/s/ ANDREA B. THOMAS	Director	February 20, 2024
Andrea B. Thomas
/s/ MING XIAN	Director	February 20, 2024
Ming Xian

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.